Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-CD30 CAR-Epstein-Barr virus-specific T lymphocytes

A preparation of allogeneic human Epstein-Barr virus (EBV)-specific T lymphocytes (EBVSTs) that have been genetically modified to express a chimeric antigen receptor (CAR) recognizing the tumor-associated antigen (TAA) cluster of differentiation 30 (CD30), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD30 CAR-EBVSTs specifically recognize and bind to CD30-expressing EBV-infected tumor cells, resulting in tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is transiently expressed on activated lymphocytes and is constitutively expressed in hematologic malignancies. EBV, a ubiquitous human herpes virus, is associated with various malignancies, including nasopharyngeal carcinoma, Hodgkin disease, non-Hodgkin lymphoma, and other lymphomas.
Synonym:allogeneic anti-CD30 CAR EBV-specific T lymphocytes
allogeneic anti-CD30 CAR-EBVSTs
allogeneic CD30.CAR-EBVSTs
Search NCI's Drug Dictionary